| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 21
| Issue : 1 | Page : 59-63 |
|
|
Interferon-gamma: Has acromegaly and diabetes an impact on such marker?
Sabreen Hamodi Hamza1, Zainab Fadhel Ashoor2, Abbas Mahdi Rahmah3
1 Department of Microbiology, College of Science for Girls, University of Baghdad, Baghdad, Iraq
2 Department of Microbiology, College of Medicine, University of Al-Mustansiriyah, Baghdad, Iraq
3 National Diabetes Center, Al-Mustansiriyah University, Baghdad, Iraq
Correspondence Address:
Dr. Sabreen Hamodi Hamza
College of Science for Girls, University of Baghdad, Baghdad
Iraq
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/mj.mj_26_21
|
|
|
Background: Acromegaly is a rare endocrine disease, its incidence is 4-6 per million per years while its prevalence is 40-60 per million. The distinctive facial characteristics are prognathism prominent forehead, and large hands and feet. This happens after the fusion of growth plates; separating acromegaly from gigantism that occurs before growth plates are closed. Interferon-gamma was checked in (80) acromegalic patients (50% are diabetics and 50% are non-diabetics) while (40) persons were regareded as healthy control group being non-diabetic, non-acromegalic. Aim of the study: To find out impact lnterferon-gamma in diabetic acromegalic versus non-diabetic acromegalic patients.Methods: Eighty acromegalic subjects were enrolled in across sectional study by measuring the level of lnterferon-gamma in the sera of diabetics and non-diabetics as 39 are diabetics while the remaining 41 patients are non-diabetic. Result: lnterferon-gammais high among diabetic acromegalic patients when compared with non-diabetic acromegalic subjects. Conclusion: Interferon gamma is high in acromegalic diabetic patients, nondiabetic acromegalic patients, and controls (100%, 97.6%, and 97.5%, respectively). Interferon gamma is elevated in patients with acromegaly only in the age group of 30–39 years, but in those with diabetes, the elevation is noticed later within the age group of 40–49 years as if concomitant diabetes delays its elevation. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
